Navigation Links
Transition in cell type parallels treatment response, disease progression in breast cancer
Date:1/31/2013

and triple-negative tumors the assay revealed a small number of epithelial cells that also expressed mesenchymal markers. The investigators then conducted EMT analysis of circulating tumors cells (CTCs) cells that break off from solid tumors and travel through the bloodstream using the second-generation CTC-chip device developed in collaboration with the MGH Center for Engineering in Medicine.

Analysis of blood samples from 41 patients with metastatic breast cancer at various stages of their treatment identified CTCs expressing mesenchymal markers (M+) in samples from 16 patients. Pre- and post-treatment samples were available from 10 patients, 5 who had responded to treatment and 5 who had not. While post-treatment samples from patients whose tumors responded showed either an overall drop in the number of CTCs captured or fewer M+ cells, samples from patients whose tumors did not respond showed an increased proportion of M+ CTCs.

The investigators had access to serial blood samples taken from one patient at various stages during the course of her disease, which included initial response to an experimental treatment, followed by treatment resistance, subsequent response to another protocol and then resumed tumor progression. Both the number of CTCs and the proportion of cells with mesenchymal markers to those with epithelial markers dropped when her tumor responded to treatment and then rose when the disease progressed. The researchers also observed that an increase in M+ CTCs in this patient was associated with the appearance of multicellular clusters of CTCs, which conflicts with the predominant model of EMT inducing single tumor cells to migrate into the bloodstream, and they found evidence that the growth factor TGF-beta may mediate EMT in cancer.

"This study provides us with a new biologic understanding of breast cancer invasion and metastasis," says Daniel Haber, MD, PhD, director of the MGH Cancer Center and co-correspo
'/>"/>

Contact: Katie Marquedant
kmarquedant@partners.org
617-726-0337
Massachusetts General Hospital
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. Topological transitions in metamaterials
2. Study Shows Transition to Practice Programs Get Nurses Employed
3. Innosight Announces Leadership Transition
4. Researchers shrink tumors and minimize side effects using tumor-homing peptide to deliver treatment
5. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
6. Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain
7. Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response
8. Intravenous Remodulin Approved for the Treatment of Pulmonary Arterial Hypertension in Most of the European Union
9. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
10. SFJ Pharma Ltd. II, Announces Agreement With Pfizer to Develop Axitinib for Adjuvant Treatment of Renal Cell Carcinoma
11. MarketsandMarkets: Global Seed Treatment Market worth $3430.3 Million by 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ON , Aug. 31, 2015 /PRNewswire/ - BIOREM Inc. ... orders totalling $5.7 million. The orders are for air emission abatement ... "Of particular note is a large order for a municipality ... equipment will be replacing a competitor,s system that failed to ... in our engineered solutions," said Derek S. Webb , ...
(Date:8/31/2015)... , Aug. 31, 2015 Research and Markets ... "Argentina Biomedical Sensors Market - Growth, Trends & ... The Argentina Biomedical Sensors market is estimated at ... over the period 2014-2020 The near future ... genetic formulation of each individual. These sensors can be ...
(Date:8/31/2015)... Aug. 31, 2015 Research and Markets ( ... "Middle East & Africa Biomedical Sensors Market - Growth, ... The Middle East ... $0.84 billion by 2018 at a CAGR of 3.26% ... will bring Biomedical sensors that are adaptable to the ...
(Date:8/31/2015)... 31, 2015  RXi Pharmaceuticals Corporation (NASDAQ: ... and developing innovative therapies primarily in the areas ... 30-day review period following the filing of the ... with the U.S. Food and Drug Administration (FDA) ... Logo -  http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
Breaking Biology Technology:Argentina Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts 2014-2020 2Middle East & Africa Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts to 2020 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4
... Calif., March 1, 2011 MAP Pharmaceuticals, Inc. (Nasdaq: ... year ended December 31, 2010. The net loss for ... to $13.4 million during the same period in 2009. The net ... compared to $9.0 million for the year ended December 31, 2009. ...
... NBS ), an international biopharmaceutical company with operations ... Smith, the Company,s Chairman and CEO, will present on Tuesday, ... Annual Analyst Conference. The Conference will be held at the ... York. Dr. Smith will present as part of Track 2: ...
... 2011 /PRNewswire-Asia-FirstCall/ -- ShengdaTech, Inc. ("ShengdaTech" or the "Company") ... nano-precipitated calcium carbonate ("NPCC") in China, today announced that ... Anhui Guo, COO and acting CFO and Mr. A. ... & Renshaw Annual China Investment Conference to be held ...
Cached Biology Technology:MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results 2MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results 3MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results 4MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results 5MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results 6MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results 7NeoStem to Present at Wall Street Forum 2011 Financial Conference on Tuesday, March 1 2NeoStem to Present at Wall Street Forum 2011 Financial Conference on Tuesday, March 1 3NeoStem to Present at Wall Street Forum 2011 Financial Conference on Tuesday, March 1 4ShengdaTech to Present at Rodman & Renshaw Annual China Investment Conference in Shanghai 2
(Date:8/18/2015)... 18, 2015  Navitas today announced that ... the Submission Content Management webinar scheduled on ... forum. Dedicated to the Implementation of Regulatory Submission ... for industry, vendors, health authorities, consultants and ... towards a standard method of implementing electronic ...
(Date:8/12/2015)... 12, 2015 As the digital ... innovation and advanced biometrics technology is accelerating beyond expectations.  ... rely on using their credit cards, the digital currency, ... for payment services led by companies in the space ... Google, Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ...
(Date:8/10/2015)... Germany , August 10, 2015 /PRNewswire/ ... world leader in Eye Tracking Technology for more than ... Eye Tracking Platform for integration into all consumer display ... designs for seamless integration of eye tracking into consumer ... and augmented reality smart glasses. Omnivision,s leading sensor technology ...
Breaking Biology News(10 mins):Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
... among the most ancient of questions: What are the origins ... in deep space reveals that the complex building blocks of ... then carried to Earth, jump-starting life. Chemists from the ... showed that conditions in space are capable of creating complex ...
... release is available in French . , ... among Canada,s most important industries and also one of the ... this wastewater has become a priority for the industry. ... by the mathematical models used to predict them. Researchers at ...
... Molecular Medicine celebrates two important milestones: the renewal of ... years, and the expansion of the Nordic EMBL network ... of Translational Neuroscience (DANDRITE) at Aarhus University, which will ... Molecular Medicine was initiated in 2007 between the University ...
Cached Biology News:New evidence that comets could have seeded life on Earth 2New method for greenhouse gas predictions 2Denmark joins the Nordic EMBL Partnership for Molecular Medicine 2
...
Anti-human L-Ficolin, Clone GN4, Monoclonal Antibody...
Jak3 Antibody Ship: Hot Store: -20 C...
B3GALT2 Immunogen: B3GALT2 (NP_003774, 324 a.a. ~ 423 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: